U.S. Markets closed

TTNP: Waiting for Revenue Turn

By John Vandermosten, CFA

NASDAQ:TTNP

READ THE FULL TTNP RESEARCH REPORT

Third Quarter 2019 Financial and Operational Results

During the third quarter and to date, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has expanded its network to include CVS Caremark, raised additional capital to support its sales and marketing efforts, received approval for additional NIDA funding and presented a pair of posters on Probuphine. Late last week, Titan submitted its quarterly update which was provided in the November 14th press release and concurrently filed 10-Q. Total revenues were $0.9 million compared to $1.7 million in the comparable period last year. Revenues for the quarter declined sequentially; however, prescriptions were similar for both periods with higher levels of patient assistance in the third quarter explaining the product revenue difference. Operating expenses were $4.6 million, up 36% from the $3.4 million expended in 3Q:18. Net loss of ($2.8) million or ($0.18) per share compares to prior year net loss of ($2.3) million and ($0.64) per share1. Net loss benefitted from a non-cash gain related to warrant valuation and would have been ($0.25) without the one-time item.

Over the last year, Titan has taken several steps to advance the commercialization of Probuphine. The company is forging partnerships with AllianceRx to help with payors and fulfillment, with AppianRx to provide patient support and with Accredo for product inventory management, billing and payment as well as deep relationships with third party payors. These agreements were signed in the first half of 2019 and are taking time to fully implement. We see value in Titan given the backdrop and the success of the drug in clinical trials and its unique profile which can provide steady drug distribution and evade diversion.

During the third quarter, Titan continued to build its relationships initiating an agreement with CVS Caremark in July for specialty product distribution, adding to its stable of distributors. The company also streamlined distribution, reducing the time from prescription to product delivery. Websites for both patients and providers have been established to help patients locate qualified providers and improve the product ordering process. Benefits verification has been reduced from over 90 days to three days with the help of Appian RX. The company is conducting targeted training of providers with a focus on the most productive prescribers and nurse practitioners. Training is taking place at drug and alcohol rehabilitation facilities, prominent medical groups and outreach is taking place at residential treatment centers, the Veteran’s Administration (VA) and federal and state prison systems. Titan is assuming numerous initiatives to stimulate sales of this important product; however, results have been slow to date. Back in the Old World, Titan partner Molteni received approval for Sixmo and is currently in pricing negotiations. First product shipments and sales are expected in 1Q:20.

Third quarter 2019 revenues of $0.9 million were comprised of $190,000 of product revenue and $757,000 of grant revenue. No license revenues were recognized. License revenues from Canada are progressing at a slow pace until pricing can be established with all the provinces and none were recognized in the quarter. Grant revenue was related to the National Institute on Drug Abuse (NIDA) nalmefene implant project.

Cost of goods sold was $188,000, equivalent to a 1.1% product gross margin. Cost of goods sold includes both the product cost, which is less than 10% of price and distribution cost, which is relatively fixed in dollar terms. Operating expenses were $4.6 million which consists of $1.6 million in research and development costs and $3.0 million in selling, general and administrative expenses. The 15% decrease in R&D expenses reflected lower Probuphine related expenses and lower compensation expenses, partially offset by an increase in expenses related to the nalmefene program. SG&A expenses doubled due to greater commercialization activities for Probuphine, higher consulting and professional fees, greater spend on outside services and travel costs.

Cash and equivalents as of September 30, 2019 were $0.9 million, compared to $9.3 million at the end of 2018. Debt was carried at $3.9 million. During the quarter, Titan received $2.0 million from equity offerings and cash burn was ($3.4) million in 3Q:19 compared to ($2.3) million in the comparable prior year period. Following the end of the quarter, Titan raised net proceeds of $8.1 million in a public offering. Management believes that cash levels are sufficient to fund the company until 3Q:20.

Exhibit I – Titan Pipeline2

Partners

During 2019 Titan announced partnerships with AllianceRx Walgreens Prime, AppianRx, Accredo, Southside Specialty Pharmacy and CVS Caremark to provide distribution and patient support services. These relationships are expected to shorten the time between product order and delivery, improve payment dynamics and improve Probuphine availability throughout the United States. Some of the changes that have been made include specialty pharmacy relationships with payors, a streamlined benefits authorization process, and holding inventory on-site. These improvements can accelerate the process of delivering Probuphine to physicians and providing timely reimbursement. AllianceRx will carry inventory, manage insurance billing, offer payment processing and ship product to the provider. AppianRx will manage benefit verification, prior authorization, appeals and co-pay/patient assistance, which should reduce time from prescription to payment. Accredo has also moved necessary paperwork to an online platform, automating the procurement process, providing real time information and satisfying REMS and verifying eligibility. Southside is anticipated to expand the presence of Probuphine into California and Texas and CVS Caremark will provide broad distribution of the implant throughout the country. We anticipate that Titan will continue to develop additional specialty pharmacy relationships to improve penetration.

Phase IV Probuphine Studies

Titan is required to conduct two Phase IV post-marketing studies. The first will be a small study estimated to cost from $3 to $4 million and will last for two to three years. It will evaluate the safety and pharmacokinetics of re-implantation of Probuphine into a previously used site on a patient’s inner upper arm as well as implantation into an alternate location in the lower abdomen. A second, observational study is still in development and is estimated to be around $8 million and will last for four years. It will assess implant procedure safety in an observational cohort design and is still being finalized. On the 3Q:19 conference call, management announced that it had postponed the post-marketing studies given Titan’s current financial condition and low volume of sales to date and have advised the FDA of their status. Titan is also participating in an industry consortium study to perform a QT prolongation study for patients treated with various forms of buprenorphine.

Raising Capital

In April 2019 Titan entered into an at the market (ATM) facility with Alliance Global Partners to sell up to $8.6 million worth of stock in the open markets. In August, the company entered into a securities purchase agreement with an institutional investor and raised $2.1 gross and $1.83 million net from the issuance of 2.85 million shares and warrants. In October, Titan sold an additional 40.3 million shares/pre-funded warrants and warrants to raise $9.1 million gross and $8.1 million net.

Molteni and the EMA

On April 29th, Titan announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the approval of the Probuphine implant in the European Union. The product will be branded Sixmo and will be indicated for substitution treatment for opioid dependence for stable patients. Following the recommendation, the CHMB was forwarded to the European Commission (EC) which provided the final approval in late June for the 28 member states. The launch of Sixmo will be accompanied by a clinical and medical affairs program and a Phase IV post marketing safety study. Initial efforts will focus on high volume addiction centers that have a wide reach into the adjacent community. Pricing approval for the first country is expected in 1Q:20 simultaneous with product shipments and we anticipate license revenues to be recognized with a delay.

Knight Therapeutics

Canadian partner Knight launched Probuphine in October 2018 and is focused on commercializing the product in rural Canadian areas for patients without ready access to a physician. The company’s press release highlighted Health Canada’s approval of the implant in 2018 and Knight’s exclusive right to distribute the drug and their launch of the product. Knight is currently in negotiations with provincial pricing authorities. When this is complete, sales and their accompanying license revenues are expected to be recognized.

Nalmefene

Beginning in October 2017, Titan conducted a feasibility assessment with Opiant to develop a product for prevention of opioid relapse and overdose in individuals with opioid use disorder (OUD). In September of 2018, Titan secured a grant from the National Institute for Drug Addiction (NIDA) to further this research using a ProNeura based six-month implantation formulation of nalmefene. The grant will provide $2.67 million during the first year and $6.08 million in the second year. The goal during the first two years is to complete IND-enabling work. Fund matching requirements exist and Titan must contribute $1.33 million in year one, but does not have an obligation in year two. Approval for the second year of the grant was given in September along with a change to the grant award terms which now allows total potential expense reimbursement of up to $8.7 million. There are an additional three years of funding that may be accessed if certain milestones are achieved. Titan expects to file an IND for ProNeura based nalmefene for the prevention of opioid relapse in 3Q:20.

Valuation

We roll our estimates forward by a year and reduce our revenue and expense estimates for 2020 and 2021. Revenues come down to reflect the slower than expected ramp in the US and Canada and our cost estimates are reduced based on the delay of the Phase IV study and management and board salary and compensation cuts in 2020. We adjust the share count and warrants outstanding to reflect the October capital raise which reduces our target price to $1.00 per share. Probuphine and the ProNeura implant are a valuable drug and technology that fill an important need in opioid use disorder and other indications where steady drug delivery is important and diversion can be a problem. We think a large investor or pharmaceutical company could acquire the shares of Titan as the current enterprise value is low compared to the potential of the product and pipeline.

Summary

Titan is developing the necessary infrastructure for growing sales despite slow progress. Near term revenue catalysts exist including development of US partnerships and Canadian and European sales. We are hopeful that the relationships with dominant specialty pharmacies will shorten the time between order and delivery and also simplify the payor approval and REMS processes.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.

________________________________

1. Note that per share amounts are adjusted for the 1:6 reverse stock consolidation that occurred on January 24, 2019. Note that share count increased dramatically from 3Q:18 to 3Q:19.

2. Source: Titan February 2019 Corporate Presentation.

  • Hedge Funds Have Never Been More Bullish On Encore Wire Corporation (WIRE)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Encore Wire Corporation (WIRE)

    We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of FLWR.V earnings conference call or presentation 26-Nov-19 10:30pm GMT

    The Flowr Corporation - CEO & Executive Director Conference Call Participants * Noel John Atkinson

  • Is Chesapeake Energy Corporation (CHK) Going To Burn These Hedge Funds ?
    Business
    Insider Monkey

    Is Chesapeake Energy Corporation (CHK) Going To Burn These Hedge Funds ?

    Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. This year hedge funds' top 20 stock picks easily bested the broader market, at 37.4% compared to 27.5%, despite there being a few duds in there like Berkshire Hathaway (even their collective wisdom isn't perfect). Chesapeake Energy Corporation (NYSE:CHK) shareholders have witnessed a decrease in hedge fund sentiment recently.

  • Hedge Funds Have Never Been More Bullish On Exponent, Inc. (EXPO)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Exponent, Inc. (EXPO)

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. In this article, we analyze how these elite funds and prominent investors traded Exponent, Inc. (NASDAQ:EXPO) based on those filings. Exponent, Inc. (NASDAQ:EXPO) has seen an increase in hedge fund sentiment recently.

  • Lululemon down after hours following Q3 results
    Business
    Yahoo Finance Video

    Lululemon down after hours following Q3 results

    Despite beating revenue and earnings expectations for Q3, Lululemon stock is down in after hours trading.

  • Hedge Funds Are Selling Albemarle Corporation (ALB)
    Business
    Insider Monkey

    Hedge Funds Are Selling Albemarle Corporation (ALB)

    Hedge funds' top 3 stock picks returned 41.7% this year and beat the S&P 500 ETFs by 14 percentage points. Is Albemarle Corporation (NYSE:ALB) undervalued? Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

  • Business
    MarketWatch

    Tailored Brands stock volatile after results beat, outlook doesn't

    Tailored Brands Inc. tlrd) shares were volatile in the extended session Wednesday after the parent company for Men's Wearhouse and Jos. A. Bank topped Wall Street expectations for the quarter but the outlook came up short.

  • These Hedge Funds Had Impeccable Timing Buying Tenable Holdings, Inc. (TENB)
    Business
    Insider Monkey

    These Hedge Funds Had Impeccable Timing Buying Tenable Holdings, Inc. (TENB)

    That's why we believe it isn't a waste of time to check out hedge fund sentiment before you invest in a stock like Tenable Holdings, Inc. NASDAQ:TENB). Tenable Holdings, Inc.

  • Is Republic First Bancorp, Inc. (NASDAQ:FRBK) Overpaying Its CEO?
    Business
    Simply Wall St.

    Is Republic First Bancorp, Inc. (NASDAQ:FRBK) Overpaying Its CEO?

    Harry Madonna has been the CEO of Republic First Bancorp, Inc. (NASDAQ:FRBK) since 2001. First, this article will compare CEO compensation with compensation at similar sized companies. Our data indicates that Republic First Bancorp, Inc. is worth US$234m, and total annual CEO compensation was reported as US$863k for the year to December 2018.

  • Is Extraction Oil & Gas, Inc. (XOG) Going To Burn These Hedge Funds ?
    Business
    Insider Monkey

    Is Extraction Oil & Gas, Inc. (XOG) Going To Burn These Hedge Funds ?

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. This year hedge funds' top 20 stock picks outperformed the S&P 500 Index by 9.9 percentage points through the end of November. Thus, we can see that the tireless research and efforts of hedge funds to identify winning stocks can work to our advantage when we know how to use the data.

  • Lenovo denies ripping off Nokia's technology
    Business
    American City Business Journals

    Lenovo denies ripping off Nokia's technology

    A court battle between two giant electronics companies – Lenovo and Nokia – continues this week. Nokia filed a federal lawsuit in North Carolina in September, accusing Lenovo of ripping off a technology it describes as being “essential to decoding video” for devices like laptops and tablets. Lenovo has benefited greatly from Nokia's innovations, which have enabled Lenovo products to more efficiently and effectively stream high quality video,” Nokia claimed in its initial suit, filed Sept.

  • Here's How P/E Ratios Can Help Us Understand SLM Corporation (NASDAQ:SLM)
    Business
    Simply Wall St.

    Here's How P/E Ratios Can Help Us Understand SLM Corporation (NASDAQ:SLM)

    The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll look at SLM Corporation's (NASDAQ:SLM) P/E ratio and reflect on what it tells us about the company's share price. SLM has a price to earnings ratio of 6.52, based on the last twelve months.

  • Another driller plans to sell assets in Marcellus, Utica
    Business
    American City Business Journals

    Another driller plans to sell assets in Marcellus, Utica

    Another big name in the Appalachian shale play plans to sell off assets in 2020. Antero Resources Corp. (NYSE: AR), a pure-play in the Marcellus and Utica with a big presence in West Virginia, announced plans to sell between $750 million and $1 billion in assets in 2020 in an effort to reduce its debt. Antero is the largest natural gas producer in West Virginia, with 547 million cubic feet of production in 2017, according to data from the West Virginia Oil and Natural Gas Association.

  • Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?

    The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile failures like hedge funds' 2018 losses in Facebook and Apple. Let's take a closer look at what the funds we track think about Arrowhead Research Corp (NASDAQ:ARWR) in this article. Arrowhead Research Corp (NASDAQ:ARWR) shareholders have witnessed a decrease in enthusiasm from smart money in recent months.

  • Is New Residential Investment Corp (NRZ) A Good Stock To Buy ?
    Business
    Insider Monkey

    Is New Residential Investment Corp (NRZ) A Good Stock To Buy ?

    Brookfield was right about politics as stocks experienced their second worst May since the 1960s due to escalation of trade disputes. Insider Monkey's flagship short hedge fund strategy outstripped the S&P 500 short ETFs by around 20 percentage points per year since its inception in May 2014.

  • Is It Too Late To Consider Buying Skyworks Solutions, Inc. (NASDAQ:SWKS)?
    Business
    Simply Wall St.

    Is It Too Late To Consider Buying Skyworks Solutions, Inc. (NASDAQ:SWKS)?

    Skyworks Solutions, Inc. (NASDAQ:SWKS) received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock's share price. Today I will analyse the most recent data on Skyworks Solutions's outlook and valuation to see if the opportunity still exists.

  • Peloton tumbles on Citron issuing 2020 price target of $5
    Business
    Yahoo Finance Video

    Peloton tumbles on Citron issuing 2020 price target of $5

    Peloton's stock tumbled after Citron Research issued a 2020 price target of $5. Yahoo Finance's Zack Guzman and Heidi Chung discuss with Payne Capital Management President Ryan Payne on YFi PM.

  • Should Twitter, Inc.’s (NYSE:TWTR) Weak Investment Returns Worry You?
    Business
    Simply Wall St.

    Should Twitter, Inc.’s (NYSE:TWTR) Weak Investment Returns Worry You?

    Today we are going to look at Twitter, Inc. (NYSE:TWTR) to see whether it might be an attractive investment prospect. To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. First up, we'll look at what ROCE is and how we calculate it.

  • Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ?

    Hedge funds' top 3 stock picks returned 41.7% this year and beat the S&P 500 ETFs by 14 percentage points. Investing in index funds guarantees you average returns, not superior returns. We are looking to generate superior returns for our readers.

  • Hedge Funds Have Never Been More Bullish On Tanger Factory Outlet Centers Inc. (SKT)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Tanger Factory Outlet Centers Inc. (SKT)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Conversely, hedge funds' top 20 large-cap stock picks generated a return of 37.4% during the same 11-month period, with the majority of these stock picks outperforming the broader market benchmark.

  • Hedge Funds Have Never Been More Bullish On Royal Bank of Canada (RY)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Royal Bank of Canada (RY)

    After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as we share valuable insight into the smart money sentiment towards Royal Bank of Canada (NYSE:RY). Royal Bank of Canada (NYSE:RY) was in 17 hedge funds' portfolios at the end of September.

  • Here is What Hedge Funds Think About Regency Centers Corp (REG)
    Business
    Insider Monkey

    Here is What Hedge Funds Think About Regency Centers Corp (REG)

    We aren't sure whether value stocks outperform growth, but we follow hedge fund investor letters to understand where the markets and stocks might be going. This article will lay out and discuss the hedge fund and institutional investor sentiment towards Regency Centers Corp (NYSE:REG). Regency Centers Corp (NYSE:REG) investors should pay attention to an increase in hedge fund interest recently.

  • Republicans Turn Up Heat on Gordon Sondland in Impeachment Hearing
    Politics
    Time

    Republicans Turn Up Heat on Gordon Sondland in Impeachment Hearing

    Congressional Republicans on Monday continued their attack against Democrats' impeachment inquiry into President Donald Trump – and this time, it involved one of their own. At multiple points in Monday's judiciary hearing, Republicans took pains to build skepticism around the testimony of European Union Ambassador Gordon Sondland, a Trump political appointee and a key actor in Trump's personal attorney Rudy Giuliani's attempts to convince Ukraine to open an investigation into Trump's chief political rival. The nearly ten-hour hearing was billed by Democrats as a vehicle for both parties to make their case about whether or not the President should be impeached.

  • Our Take On Avita Medical Limited's (ASX:AVH) CEO Salary
    Business
    Simply Wall St.

    Our Take On Avita Medical Limited's (ASX:AVH) CEO Salary

    Mike Perry has been the CEO of Avita Medical Limited (ASX:AVH) since 2017. First, this article will compare CEO compensation with compensation at similar sized companies. At the time of writing, our data says that Avita Medical Limited has a market cap of AU$1.2b, and reported total annual CEO compensation of AU$2.4m for the year to June 2019.

  • Is Thomson Reuters Corporation (TRI) Going to Burn These Hedge Funds?
    Business
    Insider Monkey

    Is Thomson Reuters Corporation (TRI) Going to Burn These Hedge Funds?

    That's why we weren't surprised when hedge funds' top 20 large-cap stock picks generated a return of 37.6% in 2019 (through the end of November) and outperformed the broader market benchmark by 9.9 percentage points.This is why following the smart money sentiment is a useful tool at identifying the next stock to invest in. Thomson Reuters Corporation (NYSE:TRI) investors should pay attention to an increase in enthusiasm from smart money lately. TRI was in 19 hedge funds' portfolios at the end of September.